Repligen

About:

Repligen is a biopharmaceutical company developing consumable products for the manufacture of biological drugs.

Website: http://www.repligen.com

Twitter/X: i/flow/login

Description:

Repligen Corporation is a life sciences company focused on the development and commercialization of high-value consumable products used in the process of manufacturing biological drugs. Our bioprocessing products are sold to major life sciences and biopharmaceutical companies worldwide. We are the leading manufacturer of Protein A affinity ligands, a critical component of Protein A resins that are used to separate and purify monoclonal antibody therapeutics. Our ATF (Alternating Tangential Flow) systems and our growth factor products are used to increase product yield during the fermentation stage of biologic drug manufacturing. In addition, we developed and market an innovative line of “ready-to-use” chromatography columns under our OPUS® and MediaScout® brands that we deliver pre-packed with our customers’ choice of resin. Repligen’s corporate headquarters are in Waltham, MA (USA) and our manufacturing facilities are located in Waltham, MA, Lund, Sweden and Weingarten, Germany.

Total Funding Amount:

$1.34B

Estimated Revenue Range:

$100M to $500M

Headquarters Location:

Waltham, Massachusetts, United States

Founded Date:

1981-01-01

Contact Email:

investors(AT)repligen.com

Founders:

Paul Schimmel

Number of Employees:

1001-5000

Last Funding Date:

2023-12-06

IPO Status:

Public

© 2025 bioDAO.ai